Fleischmann J, Catalona W J, Fair W R, Heston W D, Menon M
J Urol. 1983 Feb;129(2):312-4. doi: 10.1016/s0022-5347(17)52072-8.
We examined the incidence of prostatic cancer in patients with an elevated radioimmunoassay for prostatic acid phosphatase and clinical benign prostatic hyperplasia on digital rectal examination. Of 295 patients screened with prostatic acid phosphatase tests 17 fulfilled the criteria of having an elevated prostatic acid phosphatase, clinically benign prostate and histological examination of the prostatectomy specimen. None of the 17 patients had histological evidence of prostatic cancer. The results confirm the predictions of mathematical models that prostatic acid phosphatase is of no practical value as a screening test for prostatic cancer in patients with clinical benign prostatic hyperplasia.
我们对前列腺酸性磷酸酶放射免疫测定值升高且直肠指检临床诊断为良性前列腺增生的患者的前列腺癌发病率进行了研究。在295例接受前列腺酸性磷酸酶检测的患者中，有17例符合前列腺酸性磷酸酶升高、临床诊断为良性前列腺且前列腺切除标本组织学检查的标准。这17例患者均无前列腺癌的组织学证据。结果证实了数学模型的预测，即对于临床诊断为良性前列腺增生的患者，前列腺酸性磷酸酶作为前列腺癌筛查试验没有实际价值。
